Literature DB >> 22725265

Sensitivity and specificity of urinary ethyl glucuronide and ethyl sulfate in liver disease patients.

Scott H Stewart1, David G Koch, Douglas M Burgess, Ira R Willner, Adrian Reuben.   

Abstract

BACKGROUND: It is important to monitor alcohol use in the care of patients with liver disease, but patient self-report can be unreliable. We therefore evaluated the performance of urine ethyl glucuronide (EtG) and ethyl sulfate (EtS) in detecting alcohol use in the days preceding a clinical encounter.
METHODS: Subjects (n = 120) were recruited at a university-based hepatology clinic or during hospitalization. Alcohol consumption was ascertained by validated self-report measures. Urine EtG (cutoff 100 ng/ml) and EtS (cutoff 25 ng/ml) concentrations were assayed by a contracted laboratory using tandem mass spectrometry. The sensitivity and specificity of each biomarker in the detection of drinking during the 3 and 7 days preceding the clinic visit were determined, as well as the influence of liver disease severity on these results.
RESULTS: Urine EtG (sensitivity 76%, specificity 93%) and urine EtS (sensitivity 82%, specificity 86%) performed well in identifying recent drinking, and liver disease severity does not affect biomarker performance. After elimination of 1 false-negative self-report, urine EtG > 100 ng/ml was 100% specific for drinking within the past week, whereas 9% of the subjects without evidence of alcohol drinking for at least 1 week had EtS > 25 ng/ml.
CONCLUSIONS: Urine EtG and EtS can objectively supplement the detection of recent alcohol use in patients with liver disease. Additional research may determine optimal methods for integrating these tests into clinical care.
Copyright © 2012 by the Research Society on Alcoholism.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22725265      PMCID: PMC3459172          DOI: 10.1111/j.1530-0277.2012.01855.x

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  30 in total

1.  PHosphatidylethanol (PEth) concentrations in blood are correlated to reported alcohol intake in alcohol-dependent patients.

Authors:  Steina Aradottir; Gulber Asanovska; Stefan Gjerss; Per Hansson; Christer Alling
Journal:  Alcohol Alcohol       Date:  2006-04-19       Impact factor: 2.826

Review 2.  Urine drug screening: practical guide for clinicians.

Authors:  Karen E Moeller; Kelly C Lee; Julie C Kissack
Journal:  Mayo Clin Proc       Date:  2008-01       Impact factor: 7.616

3.  Validity of carbohydrate-deficient transferrin (%CDT), gamma-glutamyltransferase (gamma-GT) and mean corpuscular erythrocyte volume (MCV) as biomarkers for chronic alcohol abuse: a study in patients with alcohol dependence and liver disorders of non-alcoholic and alcoholic origin.

Authors:  B Hock; M Schwarz; I Domke; V P Grunert; M Wuertemberger; U Schiemann; S Horster; C Limmer; G Stecker; M Soyka
Journal:  Addiction       Date:  2005-10       Impact factor: 6.526

4.  Determination of ethyl glucuronide in hair samples by liquid chromatography/electrospray tandem mass spectrometry.

Authors:  Luca Morini; Lucia Politi; Angelo Groppi; Cristiana Stramesi; Aldo Polettini
Journal:  J Mass Spectrom       Date:  2006-01       Impact factor: 1.982

5.  Forensic confirmatory analysis of ethyl sulfate--a new marker for alcohol consumption--by liquid-chromatography/electrospray ionization/tandem mass spectrometry.

Authors:  Sebastian Dresen; Wolfgang Weinmann; Friedrich Martin Wurst
Journal:  J Am Soc Mass Spectrom       Date:  2004-11       Impact factor: 3.109

6.  Postcollection synthesis of ethyl glucuronide by bacteria in urine may cause false identification of alcohol consumption.

Authors:  Anders Helander; Ingrid Olsson; Helen Dahl
Journal:  Clin Chem       Date:  2007-08-23       Impact factor: 8.327

7.  Ethyl sulfate: a metabolite of ethanol in humans and a potential biomarker of acute alcohol intake.

Authors:  Anders Helander; Olof Beck
Journal:  J Anal Toxicol       Date:  2005 Jul-Aug       Impact factor: 3.367

8.  Urinary ethyl glucuronide testing detects alcohol consumption in alcoholic liver disease patients awaiting liver transplantation.

Authors:  Yesim Erim; Michael Böttcher; Uta Dahmen; Olof Beck; Christoph E Broelsch; Anders Helander
Journal:  Liver Transpl       Date:  2007-05       Impact factor: 5.799

9.  Evaluation of a new immunoassay for urinary ethyl glucuronide testing.

Authors:  Michael Böttcher; Olof Beck; Anders Helander
Journal:  Alcohol Alcohol       Date:  2007-10-17       Impact factor: 2.826

Review 10.  The alcohol use disorders identification test for detecting at-risk drinking: a systematic review and meta-analysis.

Authors:  Michael M Berner; Levente Kriston; Michael Bentele; Martin Härter
Journal:  J Stud Alcohol Drugs       Date:  2007-05       Impact factor: 2.582

View more
  13 in total

1.  Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with chronic liver disease.

Authors:  Scott H Stewart; David G Koch; Ira R Willner; Raymond F Anton; Adrian Reuben
Journal:  Alcohol Clin Exp Res       Date:  2014-05-21       Impact factor: 3.455

2.  Using ethyl glucuronide in urine to detect light and heavy drinking in alcohol dependent outpatients.

Authors:  Michael G McDonell; Jordan Skalisky; Emily Leickly; Sterling McPherson; Samuel Battalio; Jenny R Nepom; Debra Srebnik; John Roll; Richard K Ries
Journal:  Drug Alcohol Depend       Date:  2015-10-09       Impact factor: 4.492

3.  Determining ethyl glucuronide cutoffs when detecting self-reported alcohol use in addiction treatment patients.

Authors:  Jessica M Lowe; Michael G McDonell; Emily Leickly; Frank A Angelo; Roger Vilardaga; Sterling McPherson; Debra Srebnik; John Roll; Richard K Ries
Journal:  Alcohol Clin Exp Res       Date:  2015-04-10       Impact factor: 3.455

4.  Hair ethyl glucuronide is highly sensitive and specific for detecting moderate-to-heavy drinking in patients with liver disease.

Authors:  Scott H Stewart; David G Koch; Ira R Willner; Patrick K Randall; Adrian Reuben
Journal:  Alcohol Alcohol       Date:  2012-09-25       Impact factor: 2.826

5.  Mental Imagery to Reduce Alcohol-related harm in patients with alcohol dependence and alcohol-related liver damaGE: the MIRAGE pilot trial protocol.

Authors:  Ashwin D Dhanda; Hannah Allende; Victoria Allgar; Jackie Andrade; Matthew Peter Bailey; Lynne Callaghan; Laura Cocking; Elizabeth Goodwin; Annie Hawton; Christopher Hayward; Ben Hudson; Alison Jeffery; Angela King; Victoria Lavers; Joe Lomax; C Anne McCune; Richard Parker; Christopher Rollinson; Jonny Wilks; E Siobhan Creanor
Journal:  BMJ Open       Date:  2022-05-18       Impact factor: 3.006

Review 6.  [What ethanol metabolites as biological markers tell us about alcohol use].

Authors:  Friedrich Martin Wurst; Natasha Thon; Wolfgang Weinmann; Michel Yegles; Ulrich Preuss
Journal:  Wien Med Wochenschr       Date:  2013-12-10

7.  Ethyl glucuronide and ethyl sulfate assays in clinical trials, interpretation, and limitations: results of a dose ranging alcohol challenge study and 2 clinical trials.

Authors:  Peter I Jatlow; Ann Agro; Ran Wu; Haleh Nadim; Benjamin A Toll; Elizabeth Ralevski; Christine Nogueira; Julia Shi; James D Dziura; Ismene L Petrakis; Stephanie S O'Malley
Journal:  Alcohol Clin Exp Res       Date:  2014-04-28       Impact factor: 3.455

8.  Positive blood phosphatidylethanol concentration is associated with unfavorable waitlist-related outcomes for patients medically appropriate for liver transplantation.

Authors:  Claire S Faulkner; Collin M White; Wuttiporn Manatsathit; Bernadette Lamb; Vatsalya Vatsalya; Craig J McClain; Loretta L Jophlin
Journal:  Alcohol Clin Exp Res       Date:  2022-03-15       Impact factor: 3.928

Review 9.  Biomolecules and Biomarkers Used in Diagnosis of Alcohol Drinking and in Monitoring Therapeutic Interventions.

Authors:  Radu M Nanau; Manuela G Neuman
Journal:  Biomolecules       Date:  2015-06-29

Review 10.  Care for hospitalized patients with unhealthy alcohol use: a narrative review.

Authors:  Regina Makdissi; Scott H Stewart
Journal:  Addict Sci Clin Pract       Date:  2013-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.